دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Editorial introductions
Editor(s): Saag, Kenneth G.; Tedeschi, Sara K.; Tsokos, George C.
doi : 10.1097/BOR.0000000000000781
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p v-vi
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance
Robinson, Philip C.a; Yazdany, Jinoosb; Machado, Pedro M.c,d,e
doi : 10.1097/BOR.0000000000000783
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 111-116
This review discusses the coronavirus disease-2019 (COVID-19) Global Rheumatology Alliance (GRA), the reason for its formation, the challenges with running the registry, and future opportunities for global collaborative research in rheumatology.
Racial, ethnic, and healthcare disparities in rheumatoid arthritis
Yip, Kevina; Navarro-Mill?n, Irisa,b
doi : 10.1097/BOR.0000000000000782
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 117-121
This review highlights the available data describing racial and ethnic health disparities among patients with rheumatoid arthritis in the United States from an epidemiological, disease activity, and wider socioeconomic standpoint.
Scleroderma epidemiology update
Calderon, Leonardo Martina; Pope, Janet E.b
doi : 10.1097/BOR.0000000000000785
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 122-127
Systemic sclerosis (scleroderma, SSc) is a rare multisystem autoimmune disease characterized by autoantibodies, vasculopathy, and fibrosis of the skin and internal organs. This review aims to provide an overview and summary of the recent epidemiological studies in systemic sclerosis.
Adherence to gout guidelines: where do we stand?
Ho, Gary H.a,b; Pillinger, Michael H.a,b; Toprover, Michaela,b
doi : 10.1097/BOR.0000000000000774
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 128-134
Although gout is a common, well-recognized, and extensively researched rheumatologic disease, it continues to be underappreciated and undertreated. Although the prevalence of gout has been rising over the past several decades, adherence to urate lowering therapy continues to be suboptimal. Recent studies have underscored the potential success of guideline-directed therapy.
The role of diet in hyperuricemia and gout
Yokose, Chioa,b; McCormick, Nataliea,b,c; Choi, Hyon K.a,b
doi : 10.1097/BOR.0000000000000779
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 135-144
Although gout's cardinal feature is inflammatory arthritis, it is closely associated with insulin resistance and considered a manifestation of the metabolic syndrome. As such, both gout and hyperuricemia are often associated with major cardiometabolic and renal comorbidities that drive the persistently elevated premature mortality rates among gout patients. To that end, conventional low-purine (i.e., low-protein) dietary advice given to many patients with gout warrant reconsideration.
Medications for gout and its comorbidities: mutual benefits?
Yoshida, Kazukia,b; Choi, Hyon K.b,c; Solomon, Daniel H.a,b,d
doi : 10.1097/BOR.0000000000000784
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 145-154
To review recent literature with relevance to the management of multimorbid patients with gout, i.e., gout medication repurposed for comorbidities and vice versa.
COVID-19 and autoimmune diseases
Liu, Yua; Sawalha, Amr H.b; Lu, Qianjina,c
doi : 10.1097/BOR.0000000000000776
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 155-162
The aim of this study was to evaluate the relationship between infection with SARS-CoV-2 and autoimmunity.
Double-negative T cells in autoimmune diseases
Li, Hao; Tsokos, George C.
doi : 10.1097/BOR.0000000000000778
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 163-172
TCR??+CD4-CD8- double-negative T (DNT) cells, a principal subset of mature T lymphocytes, have been closely linked with autoimmune/inflammatory conditions. However, controversy persists regarding their ontogeny and function. Here, we present an overview on DNT cells in different autoimmune diseases to advance a deeper understanding of the contribution of this population to disease pathogenesis.
Immunopathogenesis of skin injury in systemic lupus erythematosus
Hile, Grace A.a; Kahlenberg, J. Michellea,b
doi : 10.1097/BOR.0000000000000770
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 173-180
Skin injury is the most common clinical manifestation of SLE and is disfiguring, difficult to treat, and incompletely understood. We provide an overview of recently published articles covering the immunopathogenesis of skin injury in SLE
New therapeutic approaches in systemic lupus erythematosus
Kolios, Antonios G.A.a,b; Yoshida, Nobuyaa; Tsokos, George C.a
doi : 10.1097/BOR.0000000000000772
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 181-189
This review gives an overview of the recently published clinical trials in systemic lupus erythematosus (SLE).
Update on the cellular pathogenesis of lupus
Gensous, Noémiea,b; Boizard-Moracchini, Andreab; Lazaro, Estibalizc; Richez, Christopheb,d; Blanco, Patrickb,e
doi : 10.1097/BOR.0000000000000775
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 190-196
Aberrations in the innate and in the adaptive arms of the immune system play both important roles in the initiation and progression of systemic lupus erythematosus (SLE). The aim of this study was to provide an update on the most recent findings on the cellular pathogenesis of SLE. Our overview focused particularly on results obtained over the last 18 months.
Cellular aspects of the pathogenesis of lupus nephritis
Chang, Anthonya; Clark, Marcus R.b; Ko, Kichulb
doi : 10.1097/BOR.0000000000000777
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 197-204
Lupus nephritis is a common severe manifestation of systemic lupus erythematosus. Despite recent advances in therapeutics and understanding of its pathogenesis, there are still substantial unmet needs. This review discusses recent discoveries in these areas, especially the role of tubulointerstitial inflammation (TII) in lupus nephritis.
New lupus criteria: a critical view
Aringer, Martina; Johnson, Sindhu R.b,c
doi : 10.1097/BOR.0000000000000771
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 205-210
To review the validation of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus (SLE).
The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy
Appleton, Brenna D.a; Major, Amy S.b,c
doi : 10.1097/BOR.0000000000000773
Current Opinion in Rheumatology: March 2021 - Volume 33 - Issue 2 - p 211-218
Accelerated atherosclerosis is a significant comorbidity and the leading cause of death for patients with systemic lupus erythematosus (SLE). It is now apparent that SLE-accelerated atherosclerosis is not driven solely by traditional cardiovascular risk factors, adding complexity to disease characterization and mechanistic understanding. In this review, we will summarize new insights into SLE-accelerated atherosclerosis evaluation, treatment, and mechanism.
